Targeted therapies for kidney cancer in urologic practice

Urologic Oncology: Seminars and Original Investigations

Volumn 25, Issue 5, 2007, Pages 420-432

  Haas, Naomi B ^a   Uzzo, Robert G ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Cancer; Kidney; Renal; Targeted therapy

Indexed keywords

4 (4 FLUORO 2 METHYL 5 INDOLYLOXY) 6 METHOXY 7 [3 (1 PYRROLIDINYL)PROPOXY]QUINAZOLINE; ABT 869; ALPHA INTERFERON; ALPHA2A INTERFERON; ANTINEOPLASTIC AGENT; AXITINIB; B RAF KINASE; BASIC FIBROBLAST GROWTH FACTOR; BEVACIZUMAB; E1Y03; EVEROLIMUS; FLT3 LIGAND; FOCAL ADHESION KINASE; MAMMALIAN TARGET OF RAPAMYCIN; MONOCLONAL ANTIBODY G250; PAZOPANIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN RET; PROTEIN TYROSINE KINASE INHIBITOR; RAF PROTEIN; SORAFENIB; STEM CELL FACTOR; SUNITINIB; TEMSIROLIMUS; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; VATALANIB; WX 6250;

ACNE; ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; AMYLASE BLOOD LEVEL; ANEMIA; ANGINA PECTORIS; ANOREXIA; ARTERY THROMBOSIS; ARTHRALGIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BLEEDING; BONE MARROW SUPPRESSION; BRAIN HEMORRHAGE; BRAIN INFARCTION; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CLEAR CELL CARCINOMA; CLINICAL PRACTICE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG TARGETING; DRUG WITHDRAWAL; DYSPNEA; EDEMA; EPISTAXIS; FATIGUE; FEVER; GASTROINTESTINAL HEMORRHAGE; HAIR DISCOLORATION; HAND FOOT SYNDROME; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEMOPTYSIS; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOPHOSPHATEMIA; HYPOTHYROIDISM; KIDNEY CANCER; KIDNEY CARCINOMA; LETHALITY; LIVER FUNCTION; LIVER FUNCTION TEST; LUNG ALVEOLITIS; LUNG INFILTRATE; LYMPHOCYTOPENIA; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PHOSPHATE BLOOD LEVEL; PNEUMONIA; PRIORITY JOURNAL; PROTEINURIA; PRURITUS; QT PROLONGATION; RASH; REVIEW; SIDE EFFECT; SKIN DISCOLORATION; SPEECH DISORDER; STOMATITIS; SUBARACHNOID HEMORRHAGE; SYSTEMIC THERAPY; THROMBOCYTOPENIA; THROMBOSIS; THYROID FUNCTION TEST; TRANSIENT ISCHEMIC ATTACK; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; WOUND HEALING;

ADENOCARCINOMA, CLEAR CELL; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, PAPILLARY; CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNOTHERAPY; INDOLES; KIDNEY NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN KINASE INHIBITORS; PYRIDINES; PYRROLES; SURVIVAL RATE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34548419260     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2007.05.009     Document Type: Review

References (93)

1. Jemal A., Murray T., Ward E., et al. Cancer statistics, 2005. CA Cancer J Clin 55 (2005) 10-30
2. Cohen H.T., and McGovern F.J. Renal-cell carcinoma. N Engl J Med 353 (2005) 2477-2490
3. Jayson M., and Sanders H. Increased incidence of serendipitously discovered renal cell carcinoma. Urology 51 (1998) 203-205
4. Lam J.S., Shvarts O., Leppert J.T., et al. Renal cell carcinoma 2005: New frontiers in staging, prognostication, and targeted molecular therapy. J Urol 173 (2005) 1853-1862
5. Fuhrman S.A., Lasky L.C., and Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Path 6 (1982) 655-663
6. Lam J.S., Leppert J.T., Figlin R.A., et al. Role of molecular markers in the diagnosis and therapy of renal cell carcinoma. Urology 66 Suppl 5A (2005) 1-9
7. Gonzalgo M.R., Yegnasubramanian S., Yan G., et al. Molecular profiling and classification of sporadic renal cell carcinoma by quantitative methylation analysis. Clin Cancer Res 10 (2004) 7276-7283
8. Chawla S.N., Crispen P.L., Hanlon A.L., et al. The natural history of observed enhancing renal masses: Meta-analysis and review of the world literature. J Urol 175 (2006) 425-431
9. Frank I., Blute M.L., Leibovich B.C., et al. Independent validation of the 2002 American Joint Committee on cancer primary tumor classification for renal cell carcinoma using a large, single institution cohort. J Urol 173 (2005) 1889-1892
10. Moinzadeh A., Gill I.S., Finelli A., et al. Laparoscopic partial nephrectomy: Three-year follow-up. J Urol 175 (2006) 459-462
11. Gill I.S., Remer E.M., Hasan W.A., et al. Renal cryoablation: Outcome at three years. J Urol 173 (2005) 1903-1907
12. Yagoda A., Petrylak D., and Thompson S. Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol Clin North Am 20 (1993) 303-321
13. Motzer R.J., and Russo P. Systemic therapy for renal cell carcinoma. J Urol 163 (2000) 408-417
14. Flanigan R.C., Salmon S.E., Blumenstein B.A., et al. Nephrectomy followed by interferon α-2b compared with interferon α-2b alone for metastatic renal cell cancer. N Engl J Med 345 (2001) 1655-1659
15. Motzer R.J., Bander N.H., and Nanus D.M. Renal-cell carcinoma. N Engl J Med 335 (1996) 865-875
16. Coppin C., Porzsolt F., Awa A., et al. Immunotherapy for advanced renal cell carcinoma. Cochrane Database Syst Rev 25 (2005) CD001425
17. Enquist E., Zambrano N., Zbar B., et al. Molecular genetics of renal cell carcinoma. In: Bukowski R.M., and Novick A.C. (Eds). Renal cell carcinoma: Molecular biology, immunology, and clinical management (2000), Humana Press Inc, Totowa (NJ) 79-93
18. Knudson Jr. A.G. Genetics of human cancer. Annu Rev Genet 20 (1986) 231-251
19. Uzzo R.G., and Novick A.C. von Hippel-Lindau syndrome: Clinical and molecular considerations for the urologist. AUA Update Series 18 (1999) 137-144
20. Lubensky I.A., Schmidt L., Zhuang Z., et al. Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype. Am J Pathol 155 (1999) 517-526
21. Uzzo R.G., Cairns P., Al-Saleem T., et al. The basic biology and immunobiology of renal cell carcinoma: Considerations for the clinician. Urol Clin N Am 30 (2003) 423-436
22. Baylin S.B., Herman J.G., Graff J.R., et al. Alterations in DNA methylation: A fundamental aspects of neoplasia. Adv Cancer Res 72 (1998) 141-196
23. Seizinger B.R., Rouleau G.A., Ozelius L.J., et al. von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature 332 (1988) 268-269
24. Gnarra J.R., Lerman M.I., Zbar B., et al. Genetics of renal cell carcinoma and evidence for a critical role for von Hippel-Lindau in renal tumorigenesis. Semin Oncol 22 (1995) 3-8
25. Maher E.R., and Kaelin W.G. von Hippel-Lindau disease. Medicine 76 (1997) 381-391
26. Linehan W.M., Lerman M.I., and Zbar B. Identification of the von Hippel-Lindau (VHL) gene. Its role in renal cancer. JAMA 273 (1995) 564-570
27. Foster K., Prowse A., van den Berg A., et al. Somatic mutations of the von Hippel-Lindau disease tumor suppressor gene in nonfamilial clear cell renal carcinoma. Hum Mol Genet 3 (1994) 2169-2173
28. Hatano N., Nishikawa N.S., McElgunn C., et al. A comprehensive analysis of loss of heterozygosity caused by hemizygous deletions in renal cell carcinoma using a subtraction library. Mol Carcinog 31 (2001) 161-170
29. Schmidt L., Duh F.M., Chen F., et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 16 (1997) 68-73
30. Speicher M.R., Schoell B., du Manoir S., et al. Specific loss of chromosomes 1, 2, 6, 10, 13, 17, and 21 in chromophobe renal cell carcinomas revealed by comparative genomic hybridization. Am J Pathol 145 (1994) 356-364
31. van den Berg E., van der Hout A.H., Oosterhuis J.W., et al. Cytogenetic analysis of epithelial renal-cell tumors: Relationship with a new histopathologic classification. Int J Cancer 55 (1993) 223-227
32. Kenck C., Wilhelm M., Bugert P., et al. Mutation of the VHL gene is associated exclusively with the development of nonpapillary renal cell carcinomas. J Pathol 179 (1996) 157-161
33. Fuzesi L., Cober M., and Mittermayer C. Collecting duct carcinoma: Cytogenetic characterization. Histopathology 21 (1992) 155-160
34. Rini B., Rixe O., Bukowski R., et al. AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates antitumor activity in a Phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC). Proceedings of the ASCO 2005 Annual Meeting. J Clin Oncol 23 Suppl (2005) [Abstract 4509]
35. Hurwitz H., Dowlati A., Savage S., et al. Safety, tolerability, and pharmacokinetics of oral administration of GW786034 in patients with solid tumors. Proceedings of the ASCO 2005 Annual Meeting. J Clin Oncol 23 Suppl (2005) [Abstract 3012]
36. Albert D.H., Tapang P., Magoc T.J., et al. Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol Cancer Ther 5 (2006) 995-1006
37. Wood J.M., Bold G., Buchdunger E., et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 60 (2000) 2178-2189
38. Drevs J., Muller-Driver R., Wittig C., et al. PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res 62 (2002) 4015-4022
39. Stadler W.M. Targeted agents for the treatment of advanced renal cell carcinoma. Cancer 104 (2005) 2323-2333
40. Cohen H.T., and McGovern F.J. Renal cell carcinoma. N Engl J Med 353 (2005) 2477-2490
41. Mendel D.B., Laird A.D., Xin X., et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9 (2003) 327-337
42. O'Farrell A.M., Abrams T.J., Yuen H.A., et al. SU 11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101 (2003) 3597-3605
43. Rosen L., Mulay M., Long J., et al., Cancer Institute Medical Group, Santa Monica, CA, Sugen/Pharmacia, San Francisco, CA. Phase I trial of SU011248, a novel tyrosine kinase inhibitor in advanced solid tumors. Proc Am Soc Clin Oncol 22 (2003) 191 [Abstract 765]
44. Raymond E., Faivre S., Vera K., et al., SU11248 working group, Institute Gustave Roussy, Villejuif, France, Pharmacia Co. and Sugen Inc., Villejuif, France. Final results of a Phase I and pharmacokinetic study of SU11248, a novel multi-target tyrosine kinase inhibitor, in patients with advanced cancers. Proc Am Soc Clin Oncol 22 (2003) 192 [Abstract 769]
45. Fiedler W., Serve H., Döhner H., et al. A Phase I study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia or not amenable to conventional therapy for the disease. Blood 105 (2005) 986-993
46. Motzer R.J., Rini B.I., Bukowski R.M., et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295 (2006) 2516-2524
47. Motzer R.J., Rini B.I., Michaelson M.D., et al. SU011248, a novel tyrosine kinase inhibitor, shows antitumor activity in second line therapy for patients with metastatic renal cell carcinoma: Results of a Phase II study. Proc Am Soc Clin Oncol 23 (2004) 381 [Abstract 4500]
48. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumor after failure of imatinib: A randomized controlled trial. Lancet 1006;368:1329-38.
49. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (2002) 205-216
50. Motzer R.J., Hutson T.E., Tomczak P., et al. Phase III randomized trial of sunitinib malate (SU11248) vs. interferon-α (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). Proceedings of the ASCO 2006 Annual Meeting, Part I. J Clin Oncol 24 Suppl (2006) [Abstract LBA3]
51. Wilhelm S.M., Carter C., Tang L., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64 (2004) 7099-7109
52. Ratain M.J., Eisen T., Stadler W.M., et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24 (2006) 2505-2512
53. Escudier B., Szczylik C., Eisen T., et al. Randomized Phase III trial of the RAF kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Proc Am Soc Clin Oncol 23 (2005) [Abstract 4510]
54. Van Cruijsen H., Voest E.E., Van Herpen C.M., et al. Phase I evaluation of AZD2171, a highly potent, selective VEGFR signaling inhibitor, in combination with gefitinib, in patients with advanced tumors. Proceedings of the ASCO 2006 Annual Meeting. J Clin Oncol 24 Suppl (2006) [Abstract 3017]
55. Albers M.W., Williams R.T., Brown E.J., et al. FKBP-rapamycin inhibits a cyclin-dependent kinase activity and a cyclin D1-Cdk association in early G1 of an osteosarcoma cell line. J Biol Chem 268 (1993) 22825-22829
56. Hidalgo M., and Rowinsky E.K. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 19 (2000) 6680-6686
57. Brown E.J., Albers M.W., Shin T.B., et al. A mammalian protein targeted by G1-arresting rapamycin receptor complex. Nature 369 (1994) 756-758 (Lond)
58. Dudkin L., Dilling M.B., Cheshire P.J., et al. Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin Cancer Res 7 (2001) 1758-1764
59. Neshat M.S., Mellinghoff I.K., Tran C., et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA 98 (2002) 10314-10319
60. Del Bufalo D., Ciuffreda L., Trisciuoglio D., et al. Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus. Cancer Res 66 (2006) 5549-5554
61. Atkins M.B., Hidalgo M., Stadler W.M., et al. Randomized Phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22 (2004) 909-918
62. Motzer R.J., Bacik J., Schwartz L.H., et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22 (2004) 454-463
63. Hudes G., Carducci M., Tomczak P., et al. A Phase 3, randomized, three-arm study of temsirolimus (TEMSR) or interferon-α (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma. Proceedings of the ASCO 2006 Annual Meeting. Part I. J Clin Oncol 24 Suppl (2006) [Abstract LBA4]
64. Figlin R.A., Seligson D., Wu H., et al. Characterization of the mTor pathway in renal cell carcinoma and its use in predicting patient selection for agents targeting this pathway. Proceedings of the ASCO 2005 Annual Meeting, Part I. J Clin Oncol 23 Suppl (2005) [Abstract 4539]
65. Amato R.J., Misellati A., Khan M., et al. A Phase II trial of RAD001 in patients with metastatic renal cell carcinoma (MRCC). Proceedings of the ASCO 2006 Annual Meeting, Part I. 2006. J Clin Oncol 24 Suppl (2006) [Abstract 4530]
66. Yang J.C., Haworth L., Sherry R.M., et al. A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody for metastatic renal cancer. N Engl J Med 349 (2003) 427-434
67. Rini B., Halabi S., Taylor J., et al. Cancer and Leukemia Group B 90206: A randomized Phase III trial of interferon-α or interferon-α plus antivascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clin Cancer Res 10 (2004) 2584-2586
68. Physicians' Desk Reference (PDR). 60th edition (2006), Medical Economics Co, Montvale (NJ)
69. Investigator Safety Report for CCI-779. Investigator's Brochure (2005) April
70. Veronese M.L., Mosenkis A., Flaherty K.T., et al. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 24 (2006) 1363-1369
71. Govindarajan R., Adusumilli J., Baxter D.L., et al. Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006. J Clin Oncol 24 (2006) e48
72. Ewer M.S., Vooletich M.T., Durand J.B., et al. Reversibility of trastuzumab-related cardiotoxicity: New insights based on clinical course and response to medical treatment. J Clin Oncol 23 (2005) 7820-7826
73. Ewer M.S., and Lippman S.M. Type II chemotherapy-related cardiac dysfunction: Time to recognize a new entity. J Clin Oncol 23 (2005) 2900-2902
74. Robert C., Soria J.C., Spatz A., et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 6 (2005) 491-500
75. Lokich J.J., and Moore C. Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome. Ann Intern Med 101 (1984) 798-799
76. Robert C., Faivre S., Raymond E., et al. Subungual splinter hemorrhages: A clinical window to inhibition of vascular endothelial growth factor receptors?. Ann Intern Med 143 (2005) 313-314
77. Routhouska S., Gilliam A.C., and Mirmirani P. Hair depigmentation during chemotherapy with a class III/V receptor tyrosine kinase inhibitor. Arch Dermatol 142 (2006) 1477-1479
78. Desai J., Yassa L., Marqusee E., et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 145 (2006) 660-664
79. Ewer M.S., and Lippman S.M. Type II chemotherapy-related cardiac dysfunction: Time to recognize a new entity. J Clin Oncol 23 (2005) 2900-2902
80. Sandler A., Gray R., Perry M.C., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355 (2006) 2542-2550
81. Duran I., Sin L.L., Oza A., et al. Characterization of the lung toxicity of the cell cycle inhibitor temsirolimus. Eur J Cancer 42 (2006) 1875-1880
82. Galanis E., Buckner J.C., Maurer M.J., et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A North Central Cancer Treatment Group Study. J Clin Oncol 23 (2005) 5294-5304
83. Chang S.M., Wen P., Cloughesy T., et al. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs 23 (2005) 357-361
84. Huffman T.A., Mothe-Satney I., and Lawrence Jr. J.C. Insulin-stimulated phosphorylation of lipin mediated by the mammalian target of rapamycin. Proc Natl Acad Sci USA 99 (2002) 1047-1052
85. Kunkle D.A., Haas N.B., and Uzzo R.G. Adjuvant therapy for high-risk renal cell carcinoma patients. Curr Urol Rep 8 (2007) 19-30
86. Lam J.S., Leppert J.T., Belldegrun A.S., et al. Adjuvant therapy of renal cell carcinoma: Patient selection and therapeutic options. BJU Int 96 (2005) 483-488
87. Jocham D., Richter A., Hoffman L., et al. Adjuvant autologous renal tumor cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: Phase III randomized controlled trial. Lancet 363 (2004) 594-599
88. Gordon M.S., Manola J., Fairclough D., et al. Low dose interferon-α2b + thalidomide in patients with previously untreated renal cell cancer: Improvement in progression-free survival but not quality of life or overall survival, a Phase III study of the Eastern Cooperative Oncology Group (E2898). Proc Am Soc Clin Oncol 22 (2004) [Abstract 4516]
89. Uzzo R.G., and Novick A.C. The role of nephrectomy and metastasectomy in advanced renal cell carcinoma. In: Bukowski R.M., and Novick A.C. (Eds). Renal cell carcinoma: Molecular biology, immunology, and clinical management (2000), Humana Press, Totowa (NJ) 215-228
90. Mickisch Garin A., van Poppel H., de Prijck L., et al. European Organization for Research and Treatment of Cancer (EORTC) Genitourinary Group. Radical nephrectomy plus interferon-α-based immunotherapy compared with interferon α alone in metastatic renal-cell carcinoma: A randomized trial. Lancet 358 (2001) 966-970
91. Halbert RJ, Figlin RA, Atkin MB, et al. Treatments for patients with metastatic renal cell cancer: A Rand Appropriateness Panel. Cancer 1006;107:2375-83.
92. Scappaticci FA, Fehrenbacher L, Cartwright T, et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 1005;91:173-80.
93. D'Angelica M., Kornprat P., Gonen M., et al. Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: A matched case-control study. Ann Surg Oncol 14 (2007) 759-765